Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Kaupthing Nordic Mid/Small Cap Seminar (December 2008)
25 slides from Getinge Ab Class B's conference presentation, Dec 4, 2008
Slide 1: Kaupthing Nordic Mid/Small Cap Seminar
GETINGE Kaupthing Nordic Mid/Small Cap Seminar Stockholm, 4 December
Slide 2: Agenda
BUSINESS AREA INFECTION CONTROL HEALTHCARE Agenda The Getinge Group Financial Review Q3 2008 Recent strategic developments Financial targets and drivers for growth and profitability
Slide 3: The Getinge Group
BUSINESS AREA INFECTION CONTROL HEALTHCARE The Getinge Group
Slide 4: Getinge Group Net Sales 2007
GETINGE GROUP Net Sales 2007 16 445 SEK Million* Associates* 11 632 Sales companies 86 Factories 33 Agents 300 Infection Control Medical Systems Extended Care *) 30 September, 2008
Slide 5: Infection Control: Sterilization, Disinfection
BUSINESS AREA INFECTION CONTROL Sterilization, Disinfection Production units 12 Sales companies 29
Slide 6: Extended Care: Patient Handling, Hygiene, Wound Care
BUSINESS AREA EXTENDED CARE Patient Handling, Hygiene, Wound Care Production units 11 Sales companies 28
Slide 7: Medical Systems: Surgical Workplaces, Cardiovascular, Critical Care
BUSINESS AREA MEDICAL SYSTEMS Surgical Workplaces, Cardiovascular, Critical Care Production units 10 Sales companies 29
Slide 8: Products & Solutions: NAVA and Flow-i
PRODUCTS & SOLUTIONS BUSINESS AREA INFECTION CONTROL HEALTHCARE NAVA New and unique method of synchronizing mechanical ventilation Installed base of Servo-i ventilators can be upgraded with NAVA Proprietary patient specific catheter Aim – Through clinical studies prove the reduced length of stay Flo
Slide 9: Products & Solutions: Wound Assist NPWT and Cardiohelp
PRODUCTS & SOLUTIONS BUSINESS AREA INFECTION CONTROL HEALTHCARE Wound assist NPWT 0,8 Billion EURO fast growing segment in advanced wound care Intuitive – easy to use device Strong consumables trail Leverage European customer relationships CARDIOHELP Smallest portable heart-lung machine in the world
Slide 10: Financial Review Q3 2008
BUSINESS AREA INFECTION CONTROL HEALTHCARE Financial Review Q3 2008
Slide 11: Development of organic order intake
FINANCIAL REVIEW Q3 2008 Development of organic order intake 2008 2008 Q3 YTD MS EC IC TOT MS EC IC TOT Europe 11% 0.5% 4% 5% 10% 4% -4% 4% USA and Canada 15% 31% 8% 19% 6% 14% 11% 11% Asia and Australia 18% -2% 4% 9% 10% 9% 9% 9% Rest of the world 5% 67% 121% 27% 48% 10% 80% 45% Total 12% 11% 7% 10
Slide 12: Q3 2008 Group results
FINANCIAL REVIEW Q3 2008 Q3 2008 Group results 2008 2007 Change 2008 2007 Change Q3 Q3 % YTD YTD % Net sales 4 290 3 844 11,6% 12 849 11 288 13,8% Gross margin 47,1% 44,3% 49,0% 46,0% Operating cost -1 470 -1 241 18,5% -4 514 -3 712 21,6% EBITA before restructuring 631 500 26,2% 2 020 1 581 27,8% %
Slide 13: Recent strategic developments
Recent strategic developments
Slide 14: Getinge strategic cornerstones
GETINGE STRATEGIC CORNERSTONES Global leadership We strive to be a global No 1 or No 2 in the product areas focused. Market leadership will help us attain cost leadership through scale. Solution provider We strive to combine the strength of our leading product positions and the depth of our know-how
Slide 15: Huntleigh integration
HUNTELIGH INTEGRATION BUSINESS AREA INFECTION CONTROL HEALTHCARE The integration of Huntleigh will be completed by Q4 2008 Cost synergies will exceed targeted 300 Msek p.a. New plant structure in place Joint sales and marketing organization under a single brand Improved logistics 3 PL Common IT Infr
Slide 16: Boston Scientific cardiac and vascular surgery acquisition
THE BOSTON SCIENTIFIC CARDIAC AND VASCULAR BUSINESS AREA INFECTION CONTROL SURGERY ACQUISITION HEALTHCARE Plans and actions in place to generate planned revenue synergies from 2009 onward Sales of revascularization products through Medical Systems existing sales channels on the OUS markets Sales of
Slide 17: Acquisition of Datascope Corp. USA
ACQUISITION OF DATASCOPE CORP. USA The acquisition of Datascope is consitent with Getinge’s ambition of building a leading Cardiovascular position with focus on: Cardiac Surgery Vascular Interventions Cardiac Assist (short – long term)
Slide 18: Datascope market position in counterpulsation therapy
ACQUISITION OF DATASCOPE CORP. USA Datascope retains over 70 % of the global market for Counterpulsation therapy Intra Aortic Baloon Pumps Baloon Catheters Vascular Closure Devices
Slide 19: Datascope product portfolio and pipeline
ACQUISITION OF DATASCOPE CORP. USA Datascope has a strong product portfolio and a promising pipeline in the Endovascular Stent and Vascular Surgery market Vascular Grafts Peripheral Stents Stentgrafts
Slide 20: Financial targets and synergies
ACQUISITION OF DATASCOPE CORP. USA BUSINESS AREA INFECTION CONTROL HEALTHCARE Financial targets and synergies We expect revenue synergies from geographical and product complementarities to deliver organic top line growth of 10 % or better Elimination of duplication of sales infrastructure in 12 mark
Slide 21: Financial Targets and drivers for growth and profitability
BUSINESS AREA INFECTION CONTROL HEALTHCARE Financial Targets and drivers for growth and profitability
Slide 22: Group Financial targets
BUSINESS AREA INFECTION CONTROL HEALTHCARE Group Financial targets 15% year over year average growth of pre tax earnings Development of existing positions: 7–8% Acquisition of globally leading product lines: 7–8% To reach and maintain an EBITA-margin of 18-19 % (current structure) Cash flow generati
Slide 23: Growth Drivers
BUSINESS AREA INFECTION CONTROL HEALTHCARE Growth Drivers Getinge believes it can generate growth above market rates in the medium term Increased exposure to faster growing economies through investments in sales infrastructure in emerging markets Expansion of available market through product innovat
Slide 24: Drivers for expanding operating margins
BUSINESS AREA INFECTION CONTROL HEALTHCARE Drivers for expanding operating margins Cost based synergies from recent acquisition in combination with declining restructuring costs Initiatives to improve our existing supply-chain and structure Acquisition of businesses with higher operating margins
Slide 25: \ GETINGE
\ GETINGE GETINGE
Getinge — Kaupthing Nordic Mid/Small Cap Seminar (December 2008) on 6ix